Role of the Immune Environment in Response to Therapy in Breast Cancer

Launched by ABRAMSON CANCER CENTER AT PENN MEDICINE · May 25, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at how the immune system affects the response to treatment in different types of breast cancer. Researchers will compare tissue samples from women with estrogen receptor-positive (ER+) and HER2-negative breast cancers to those from women with triple-negative breast cancer (TNBC) and HER2-positive breast cancer. This study aims to help understand why some patients respond better to treatments than others, but it won't change any current treatments for participants.

To be eligible for this study, women must be 18 years or older and have non-metastatic breast cancer, meaning the cancer hasn't spread to other parts of the body. Participants will be recruited from the University of Pennsylvania Health System and will need to undergo surgery for their breast cancer. The study is currently looking for participants, and it’s important to note that men, children, and pregnant individuals cannot participate. If you're eligible and choose to join, you'll be helping researchers learn more about how your immune system interacts with different types of breast cancer, which could lead to better treatments in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion criteria:
• • Women 18 years of age or older with non-metastatic breast cancer undergoing surgical resection in the University of Pennsylvania Health System.
• Exclusion criteria:
• • Males Children Pregnant individuals